M
Michele Del Vecchio
Researcher at University of Milan
Publications - 90
Citations - 6384
Michele Del Vecchio is an academic researcher from University of Milan. The author has contributed to research in topics: Ipilimumab & Melanoma. The author has an hindex of 27, co-authored 89 publications receiving 4826 citations. Previous affiliations of Michele Del Vecchio include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,C. Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Paola Queirolo,Rene Gonzalez,Ragini R. Kudchadkar,Michael Smylie,Nicolas Meyer,Laurent Mortier,Michael B. Atkins,Georgina V. Long,Shailender Bhatia,Céleste Lebbé,Piotr Rutkowski,Kenji Yokota,Naoya Yamazaki,Tae M. Kim,Veerle de Pril,J Sabater,Anila Qureshi,James Larkin,Paolo A. Ascierto +33 more
TL;DR: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
Journal ArticleDOI
Interleukin-12: biological properties and clinical application.
Michele Del Vecchio,Emilio Bajetta,Stefania Canova,Michael T. Lotze,Amy Wesa,Giorgio Parmiani,Andrea Anichini +6 more
TL;DR: More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies,Philippe Saiag,Caroline Robert,Jean-Jacques Grob,Keith T. Flaherty,Ana Arance,Vanna Chiarion-Sileni,Luc Thomas,Thierry Lesimple,Laurent Mortier,Stergios J. Moschos,David Hogg,Ivan Marquez-Rodas,Michele Del Vecchio,Céleste Lebbé,Nicolas Meyer,Ying Zhang,Yingjie Huang,Bijoyesh Mookerjee,Georgina V. Long +19 more
TL;DR: Results from the phase 2 COMBI-MB trial provide evidence of clinical benefit with dabrafenib plus trametinib and support the need for additional research to further improve outcomes in patients with melanoma brain metastases.
Journal ArticleDOI
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto,Michele Del Vecchio,Caroline Robert,Andrzej Mackiewicz,Vanna Chiarion-Sileni,Ana Arance,Céleste Lebbé,Lars Bastholt,Omid Hamid,Piotr Rutkowski,Catriona M. McNeil,Claus Garbe,Carmen Loquai,Brigitte Dréno,Luc Thomas,Jean-Jacques Grob,Gabriella Liszkay,Marta Nyakas,Ralf Gutzmer,Joanna Pikiel,Florent Grange,Christoph Hoeller,Virginia Ferraresi,Michael Smylie,Dirk Schadendorf,Laurent Mortier,Inge Marie Svane,Delphine Hennicken,Anila Qureshi,Michele Maio +29 more
TL;DR: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival, but with increased treatment-related adverse events, while the treatment landscape for advanced melanomas has changed since this study was initiated.
Journal ArticleDOI
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer,Dirk Schadendorf,Paolo A. Ascierto,Ana Arance,Caroline Dutriaux,Anna Maria Di Giacomo,Piotr Rutkowski,Michele Del Vecchio,Ralf Gutzmer,Mario Mandalà,Luc Thomas,Lev V. Demidov,Claus Garbe,David Hogg,Gabriella Liszkay,Paola Queirolo,Ernesto Wasserman,James Ford,Marine Weill,L. Andres Sirulnik,Valentine Jehl,Viviana Bozón,Georgina V. Long,Keith T. Flaherty +23 more
TL;DR: Binimetinib improved progression-free survival compared with dacarbazine and was tolerable, and might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy.